UNICA IRIS Institutional Research Information System

MARONGIU, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 101152
NA - Nord America 7668
AS - Asia 756
AF - Africa 22
OC - Oceania 22
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 2
Totale 109640
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 99196
US - Stati Uniti d'America 7596
UA - Ucraina 661
CN - Cina 572
SE - Svezia 552
FI - Finlandia 189
DE - Germania 188
GB - Regno Unito 162
VN - Vietnam 59
CA - Canada 58
FR - Francia 51
BE - Belgio 31
RU - Federazione Russa 29
IN - India 25
NL - Olanda 24
IR - Iran 22
ES - Italia 20
AU - Australia 19
TW - Taiwan 10
BR - Brasile 9
JP - Giappone 9
KR - Corea 9
MX - Messico 9
TR - Turchia 9
IQ - Iraq 7
TH - Thailandia 7
BG - Bulgaria 6
CH - Svizzera 6
IE - Irlanda 6
ZA - Sudafrica 6
ID - Indonesia 5
RO - Romania 5
SD - Sudan 5
CL - Cile 4
DK - Danimarca 4
EG - Egitto 4
MT - Malta 4
MY - Malesia 4
CO - Colombia 3
CZ - Repubblica Ceca 3
NZ - Nuova Zelanda 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
CR - Costa Rica 2
EE - Estonia 2
EU - Europa 2
HR - Croazia 2
IL - Israele 2
KW - Kuwait 2
MA - Marocco 2
PH - Filippine 2
PK - Pakistan 2
PL - Polonia 2
PY - Paraguay 2
RS - Serbia 2
AL - Albania 1
AM - Armenia 1
AN - Antille olandesi 1
BD - Bangladesh 1
CU - Cuba 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HK - Hong Kong 1
HU - Ungheria 1
KE - Kenya 1
LB - Libano 1
LT - Lituania 1
MZ - Mozambico 1
NG - Nigeria 1
PT - Portogallo 1
SA - Arabia Saudita 1
SG - Singapore 1
TN - Tunisia 1
Totale 109640
Salva come PNG Salva come JPEG
Città #
Cagliari 98692
Fairfield 1368
Woodbridge 840
Houston 647
Chandler 644
Seattle 549
Wilmington 524
Ashburn 523
Ann Arbor 463
Cambridge 449
Nyköping 445
Jacksonville 348
Dearborn 158
Nanjing 112
Beijing 109
Boston 103
San Diego 86
Helsinki 75
Dong Ket 56
Hebei 55
Shenyang 48
Redwood City 46
Milan 40
Nanchang 36
Changsha 35
Toronto 35
Brussels 31
Guangzhou 30
Jiaxing 29
Verona 24
Orange 23
Millbury 22
London 20
Norwalk 20
Tianjin 19
Jinan 17
Mountain View 17
Redmond 16
Ningbo 15
Rome 14
Boardman 13
Los Angeles 13
Atlanta 12
Auburn Hills 12
Hefei 12
Quartu Sant'elena 11
Saint Petersburg 11
Taizhou 9
Zhengzhou 9
Acate 8
Augusta 8
Taipei 8
Torino 7
Chicago 6
Sofia 6
Sydney 6
Ankara 5
Delhi 5
Elmas 5
Hangzhou 5
Kunming 5
Mumbai 5
New York 5
Nuoro 5
Phoenix 5
Sassari 5
Stockholm 5
Turin 5
Valladolid 5
Alghero 4
Amsterdam 4
Andover 4
Bangkok 4
Cleveland 4
Figline Valdarno 4
Fuzhou 4
Hixson 4
Jakarta 4
Munich 4
Nocera Superiore 4
San Mateo 4
Tehran 4
Zanjan 4
Agordo 3
Birkirkara 3
Bucharest 3
Durban 3
Gunzenhausen 3
Hanoi 3
Leawood 3
Montréal 3
Rotterdam 3
Santiago 3
Tabriz 3
Walnut 3
Bari 2
Bergamo 2
Berlin 2
Bhubaneswar 2
Bogotá 2
Totale 107101
Salva come PNG Salva come JPEG
Nome #
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2274
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2228
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2180
Acquired factor VIII inhibitor and subsequent development of non-Hodgkin's lymphoma: a case report and review of the literature 2124
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2102
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2047
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 1962
Olanzapine-associated portal and superior mesenteric vein thrombosis 1956
A retrospective cohort study of patients with pulmonary embolism: The impact of comorbidities on patient's outcome 1765
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 1704
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 1596
A Sardinian Family with Factor XI Deficiency 1580
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 1575
A “Catastrophic” Heparin-Induced Thrombocytopenia 1380
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1368
Point-of-care testing INR: an overview 1367
Vaping effects on asthma: results from a web survey and clinical investigation 1348
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1344
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1331
Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience 1327
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1300
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1292
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1228
Direct oral anticoagulants: what can we learn? 1215
Fibrinogen and D-dimer levels in autoimmune subclinical and overt hypothyroidism and effects of levothyroxine treatment. 1176
Pulmonary thrombosis in 2019-nCoV pneumonia? 1163
T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection 1161
The hemostatic system. 1st Part 1145
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1132
Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections 1108
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1101
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1054
Optimizing tailored DIEP flap insetting in unilateral immediate free autologous breast reconstruction 1049
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1044
Uneven hepatic iron and phosphorus distribution in b-thalassemia 1029
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 1029
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA(2)DS(2)VASc 1 or 2): a treatment dilemma 1022
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1022
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1010
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 990
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 973
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 953
[Immunological aspects in anti-HIV seronegative drug addicts. Correlation with the duration of heroin addiction and other viral infections]. FT Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell'eroina e con altre infezioni virali. 940
Thyroid disorders and hypocoagulability 923
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 895
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 894
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 867
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 851
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 851
Aspetti immunologici nei tossicodipendenti anti-HIV sieronegativi. Correlazione con la durata di assunzione dell’eroina e con altre infezioni virali 834
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 833
null 824
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 820
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago 809
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 804
Sampling variability in hepatic iron concentration in beta-thalassemia 804
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 803
The Italian START-Register on anticoagulation with focus on atrial fibrillation 803
null 772
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 765
Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission 753
Center-related determinants of VKA anticoagulation quality: A prospective, multicenter evaluation 746
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal 731
Rheumatoid arthritis and thrombosis 708
Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes 689
null 679
Start-register (Survey on anticoagulated patients register): the first year of activity 675
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 655
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 654
A guide to oral anticoagulation 645
null 644
Amoxicillina-acido clavulanico ed anticoagulanti orali:un’associazione potenzialmente pericolosa 641
null 633
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 620
null 617
null 616
Management of special conditions in patients on vitamin K antagonists 607
Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency 591
null 579
null 573
Special indications for vitamin K antagonists: a review 570
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 562
null 547
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 540
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 525
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 499
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA) 493
null 491
Heparins and 2019-nCoV infection: a narrative review 468
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 463
A pilot survey on chronic oral anticoagulation 456
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study 454
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2(V617F) mutation 443
Superior sagittal sinus thrombosis after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of the prothrombin G20210A mutation and 4G/4G genotype 441
null 440
null 436
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders 417
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 410
Relationship between elevated fibrinopeptide A levels and alpha-2-antiplasmin. 407
[Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis]. FT La precallicreina plasmatica (fattore Fletcher) nella cirrosi epatica. 397
Totale 96361
Salva come PNG Salva come JPEG
Categoria #
all - tutte 122767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 122767
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20184280 0000 00 00 11828388271433
2018/20198020 40189414851182 804711 630273 278369462531
2019/202025682 1517701168563 89896797 3406893 619565508956
2020/202139251 1092152815059267 79914631 37832511 825218119142023
2021/20229222 907687421666 761722 615508 71295811501115
2022/202311463 1328187617231251 12481495 7141137 691000
Totale 110100